PALOMA-3 SC Amivantamab
PALOMA-3: Phase III Noninferiority Trial of SC Amivantamab vs IV Amivantamab Each With Lazertinib in Progressive Advanced EGFR-Mutated NSCLC

Released: June 04, 2024

Expiration: June 03, 2025

Activity

Progress
1
Course Completed